Elham Khodarahmi

Consultant at Rescop
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Netherlands, NL
Languages
  • English Full professional proficiency
  • Swedish Elementary proficiency
  • Persian Native or bilingual proficiency
  • Dutch Limited working proficiency

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • Netherlands
    • IT Services and IT Consulting
    • 1 - 100 Employee
    • Consultant
      • Sep 2022 - Present
    • United States
    • Pharmaceutical Manufacturing
    • Pharmacist
      • 2018 - 2019

      • Providing pharmacological information and advising patients about medicines, including how to take them, what reactions may occur, and answering patients' questions • Dispensing medications by compounding, packaging, and labeling pharmaceuticals • Controlling medications, monitoring drug therapies and interactions • purchasing, storage, financial management, deal with insurance companies • Providing prompt, efficient, and friendly customer service • Providing pharmacological information and advising patients about medicines, including how to take them, what reactions may occur, and answering patients' questions • Dispensing medications by compounding, packaging, and labeling pharmaceuticals • Controlling medications, monitoring drug therapies and interactions • purchasing, storage, financial management, deal with insurance companies • Providing prompt, efficient, and friendly customer service

    • Iran
    • Government Administration
    • 100 - 200 Employee
    • Responsible for pharmaceutical affairs
      • 2016 - 2018

Education

  • Isfahan University of Medical Sciences
    Doctor of Pharmacy (Pharm.D.), Pharmacy
    2008 - 2014
  • CVO Gent
    Dutch, B1
    2020 - 2021
  • Language Center of Gent University (Universitair Centrum voor Talenonderwijs)
    B1 and studying B2
    2021 - 2021

Community

You need to have a working account to view this content. Click here to join now